ロード中...
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study
Although immune checkpoint inhibitor therapy has led to modest response rates in patients with advanced urothelial cancer, the combination of chemotherapy with immune checkpoint inhibition has not been previously clinically studied. In this phase I study, we found that the combination of pembrolizum...
保存先:
| 出版年: | Clin Genitourin Cancer |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6450697/ https://ncbi.nlm.nih.gov/pubmed/30166228 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.07.004 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|